Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Vipoma 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gastrinoma 1Extrapancreatic Neuroendocrine Tumor 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 10Iodine-131 8selpercatinib 5Thyrotropin Alfa 5trametinib 4dabrafenib 4Vemurafenib 4Thyroidectomy 4lenvatinib 3cabozantinib 3Transurethral Resection of Prostate 3Sunitinib 3Specimen Handling 3Sorafenib 3Radiofrequency Ablation 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vandetanib 2entrectinib 2cobimetinib 2X-Rays 2Trastuzumab 2Thyroid (USP) 2Surgical Procedures, Operative 2Rosiglitazone 2Radiotherapy 2Nivolumab 2Lymph Node Excision 2Interviews as Topic 2Gefitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × Thalidomide × Endocrine × Clear all
NCT00026533 2017-06-06

Thalidomide in Treating Patients With Thyroid Cancer

University of Kentucky

Phase 2 Completed
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡